Displaying drugs 6976 - 7000 of 8178 in total
Poseltinib
Poseltinib is under investigation in clinical trial NCT02628028 (A Study of LY3337641 in Rheumatoid Arthritis).
Investigational
Matched Description: … Poseltinib is under investigation in clinical trial NCT02628028 (A Study of LY3337641 in Rheumatoid Arthritis …
OM85
OM-85, a bacterial extract, is an immunomodulator of interferon-β production and inflammasome activity.
Investigational
Matched Description: … OM-85, a bacterial extract, is an immunomodulator of interferon-β production and inflammasome activity …
Phorbol 12-myristate 13-acetate diester
Phorbol 12-myristate 13-acetate diester is an inducer of neutrophil extracellular traps (NETs).
Investigational
Matched Description: … Phorbol 12-myristate 13-acetate diester is an inducer of neutrophil extracellular traps (NETs). …
EXOB-001
EXOB-001 consists of extracellular vesicles derived from cultured human umbilical cord mesenchymal stromal cells.
Investigational
Matched Description: … EXOB-001 consists of extracellular vesicles derived from cultured human umbilical cord mesenchymal stromal …
EXT608
EXT608 is a long-acting PTH derivative under investigation for the treatment of hyperparathyroidism.
Investigational
Matched Description: … EXT608 is a long-acting PTH derivative under investigation for the treatment of hyperparathyroidism. …
SPP 301
SPP301 (Avosentan) is a potent and highly selective ET[A] receptor blocker and is clinically investigated in diabetic nephropathy. This study was designed to evaluate whether avosentan influences the pharmacokinetics of steroid oral contraceptives.
Investigational
Matched Description: … This study was designed to evaluate whether avosentan influences the pharmacokinetics of steroid oral …
Bombesin
Bombesin is under investigation in clinical trial NCT01205321 (PET/CT Imaging for Radiation Dosimetry, Plasma Pharmacokinetics, Biodistribution, Safety and Tolerability and Diagnostic Performance of BAY86-7548 in Patients With Prostate Cancer and Healthy Volunteers).
Investigational
Matched Description: … Dosimetry, Plasma Pharmacokinetics, Biodistribution, Safety and Tolerability and Diagnostic Performance of …
Pimivalimab
Pimivalimab is under investigation in clinical trial NCT04549025 (Study of PD-1 Inhibitor JTX-4014 Alone and in Combination With Vopratelimab in Biomarker-selected Subjects With Metastatic NSCLC After One Prior Platinum-containing Regimen).
Investigational
Matched Description: … Pimivalimab is under investigation in clinical trial NCT04549025 (Study of PD-1 Inhibitor JTX-4014 Alone …
ARO-ANG3
ARO-ANG3 is a subcutaneously administered RNA interference (RNAi)-based investigational medicine targeting angiopoietin-like protein 3 (ANGPTL3). It was granted an orphan drug designation for the treatment of homozygous familial hypercholesterolemia (HoFH).
Investigational
Matched Description: … It was granted an orphan drug designation for the treatment of homozygous familial hypercholesterolemia …
CER-001
CER-001 is a negatively charged lipoprotein particle comprising human recombinant apolipoprotein A-I and two phospholipids: sphingomyelin and dipalmitoylphosphatidylglycerol. It is under investigation for the treatment of lecithin-cholesterol acyltransferase (LCAT) deficiencies.
Investigational
Matched Description: … [L48290] It is under investigation for the treatment of lecithin-cholesterol acyltransferase (LCAT) deficiencies …
AVR-RD-04
AVR-RD-04 is an investigational gene therapy for cystinosis. It consists of autologous CD34+ enriched cells transduced with a lentiviral vector containing RNA resulting in codon-optimized cDNA encoding for functional human cystinosin.
Investigational
Matched Description: … It consists of autologous CD34+ enriched cells transduced with a lentiviral vector containing RNA resulting …
BGT-DTDS
BGT-DTDS is an investigational gene therapy comprising an adeno-associated viral vector type 2 (AAV2) encoding the human SLC6A3 gene. It is under investigation for the treatment of dopamine transporter deficiency syndrome (DTDS).
Investigational
Matched Description: … It is under investigation for the treatment of dopamine transporter deficiency syndrome (DTDS). …
Batroxobin
Batroxobin is a defibrinogenating hemostatic agent derived from the venom of a pit viper, Bothrops atrox moojeni. In addition to batroxobin, the venom of Bothrops atrox has a composition of 10.2% neutral carbohydrate. Batroxobin is a serine protease, which cleaves the 16 Arginine - 17 Glycine bond in fibrinogen. The...
Experimental
Matched Description: … In addition to batroxobin, the venom of Bothrops atrox has a composition of 10.2% neutral carbohydrate ... The MW of batroxobin is approximately 43,000 g/mol-1, and it contains 231 amino acids. ... Batroxobin is a defibrinogenating hemostatic agent derived from the venom of a pit viper, Bothrops atrox …
Eprotirome
Eprotirome which is a compound with promising properties for treatment of obesity and dyslipidemia. Eprotirome increases the body’s energy consumption and reduces body weight and markedly reduces blood lipids and blood glucose.
Investigational
Matched Description: … Eprotirome which is a compound with promising properties for treatment of obesity and dyslipidemia. …
Danvatirsen
Danvatirsen is under investigation in clinical trial NCT03334617 (Phase II Umbrella Study of Novel Anti-cancer Agents in Patients With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy.).
Investigational
Matched Description: … Danvatirsen is under investigation in clinical trial NCT03334617 (Phase II Umbrella Study of Novel Anti-cancer …
Inarigivir
Inarigivir is under investigation in clinical trial NCT03434353 (Study to Evaluate the Antiviral Activity of Inarigivir (GS-9992) Plus Tenofovir Alafenamide (TAF) for 12 Weeks in Adults With Chronic Hepatitis B (CHB)).
Investigational
Matched Description: … Inarigivir is under investigation in clinical trial NCT03434353 (Study to Evaluate the Antiviral Activity of …
Gastric inhibitory polypeptide
Gastric inhibitory polypeptide is under investigation in clinical trial NCT03081676 (The Effect of GIP and GLP-1 on Insulin and Glucagon Secretion in Patients With HNF1A-diabetes Treated With or Without Sulphonylurea).
Investigational
Matched Description: … Gastric inhibitory polypeptide is under investigation in clinical trial NCT03081676 (The Effect of GIP …
GS-6620
GS-6620 is under investigation in clinical trial NCT01316237 (A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of GS-6620 in Treatment Naïve Subjects With Chronic Hepatitis C Virus Infection).
Investigational
Matched Description: … trial NCT01316237 (A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of …
JNJ-54175446
JNJ-54175446 is under investigation in clinical trial NCT02933762 (A Study in Healthy Participants to Evaluate the Effect of JNJ-54175446 on Amyloid Biomarkers and Cytokine Profiles in Cerebrospinal Fluid and Plasma).
Investigational
Matched Description: … investigation in clinical trial NCT02933762 (A Study in Healthy Participants to Evaluate the Effect of …
Dovramilast
Dovramilast is under investigation in clinical trial NCT01300208 (To Evaluate the Preliminary Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of CC-11050 in Subjects With Discoid Lupus Erythematosus and Subacute Cutaneous Lupus Erythematosus).
Investigational
Matched Description: … (To Evaluate the Preliminary Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of …
SEA-CD70
SEA-CD70 is an investigational humanized, non-fucosylated monoclonal antibody targeting CD70. SEA-CD70 is under investigation in clinical trial NCT04227847 (A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies).
Investigational
Matched Description: … SEA-CD70 is under investigation in clinical trial NCT04227847 (A Safety Study of SEA-CD70 in Patients …
NNZ-2591
NNZ-2591 (cyclo-L-glycyl-L-2-allylproline) is an investigational synthetic analog of cyclic glycine-proline (cGP), a breakdown product of human insulin-like growth factor 1 (IGF-1), that has been chemically modified to increase its half-life, stability, and oral bioavailability. It is currently under development by Neuren Pharmaceuticals for the symptomatic treatment of Angelman, Phelan-McDermid, and...
Investigational
Matched Description: … NNZ-2591 (cyclo-L-glycyl-L-2-allylproline)[A189390] is an investigational synthetic analog of cyclic ... glycine-proline (cGP), a breakdown product of human insulin-like growth factor 1 (IGF-1), that has been ... [L11106] It is currently under development by Neuren Pharmaceuticals for the symptomatic treatment of …
Rocatinlimab
Rocatinlimab is a subcutaneously administered anti-OX40 antibody developed for the treatment of moderate-to-severe atopic dermatitis. In clinical trials, it has shown significant efficacy and safety compared to a placebo. The drug works by targeting the OX40 receptor, which plays a role in the immune response associated with atopic dermatitis. Despite...
Investigational
Matched Description: … Despite its promising results, the long-term safety of rocatinlimab requires further investigation, as ... Rocatinlimab is a subcutaneously administered anti-OX40 antibody developed for the treatment of moderate-to-severe ... Additionally, the diverse genetic backgrounds of patients may influence the drug’s effectiveness and …
MEM 1414
MEM 1414 is a PDE4 inhibitor that is being evaluated for the treatment of Alzheimer’s disease. This drug candidate has completed Phase 1 clinical trials. MEM 1414 works by blocking phosphodiesterase, an enzyme that breaks down an important brain chemical, cyclic AMP. It appears to work in the area of...
Investigational
Matched Description: … It appears to work in the area of the brain where new memories are formed. ... MEM 1414 is a PDE4 inhibitor that is being evaluated for the treatment of Alzheimer’s disease. …
Sirna-027
Sirna-027 is a chemically modified short interfering RNA(siRNA) targeting Vascular Endothelial Growth Factor Receptor-1(VEGFR-1). VEGFR-1 is a key component of the clinically validated vascular endothelial growth factor (VEGF) pathway. Sirna-027 is developed by Sirna Therapeutics and is under the phase I of clinical trails. It is used to treat Macular...
Investigational
Matched Description: … Sirna-027 is developed by Sirna Therapeutics and is under the phase I of clinical trails. ... VEGFR-1 is a key component of the clinically validated vascular endothelial growth factor (VEGF) pathway …
Displaying drugs 6976 - 7000 of 8178 in total